Merck, Medtronic Stocks Worth Investing in
This is a news story, published by Yahoo Finance, that relates primarily to Keytruda news.
Keytruda news
For more Keytruda news, you can click here:
more Keytruda newsdrug discoveries news
For more drug discoveries news, you can click here:
more drug discoveries newsYahoo Finance news
For more news from Yahoo Finance, you can click here:
more news from Yahoo FinanceAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
best stocks. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest research company Evaluate Pharma news, Stocks news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
innovative medicinesThe Motley Fool
•2 Dividend Stocks to Buy and Never Sell
80% Informative
Merck has the top-selling cancer drug in the world, Keytruda .
Medtronic has long been a leader in the medical-device market, and is one of the largest companies in this field by market cap.
The company has increased its payouts for 47 consecutive years , meaning it's inching toward Dividend King status.
The Motley Fool has positions in and recommends Intuitive Surgical and Merck . The Motley Fool recommends Medtronic and recommends the following options: long January 2026 $ 75 calls on Medtronic and short January 2026 $ 85 calls on Medtronic . The Motley Fool has a disclosure policy. 2 Dividend Stocks to Buy and Never Sell was originally published by The Motley Fool .
VR Score
77
Informative language
75
Neutral language
36
Article tone
semi-formal
Language
English
Language complexity
47
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
7
Source diversity
2
Affiliate links
no affiliate links